deferoxamine has been researched along with indazoles in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asaka, Y; Hara, A; Kusakari, J; Tabuchi, K; Tsuji, S | 1 |
| Beart, PM; Chu, PW; Jones, NM | 1 |
| Khan, SA; Luo, W; Nanduri, J; Prabhakar, NR; Semenza, GL; Yuan, G | 1 |
| Aoki, M; Harada, T; Hirose, K; Ichise, K; Kato, T; Sato, M; Takai, Y; Takeda, K; Wada, Y | 1 |
4 other study(ies) available for deferoxamine and indazoles
| Article | Year |
|---|---|
Ischemia-reperfusion injury of the cochlea: effects of an iron chelator and nitric oxide synthase inhibitors.
Topics: Action Potentials; Animals; Auditory Threshold; Blood Flow Velocity; Blood Pressure; Cochlea; Deferoxamine; Enzyme Inhibitors; Guanidines; Guinea Pigs; Indazoles; Iron Chelating Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Reperfusion Injury | 2001 |
Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes.
Topics: Animals; Astrocytes; Cell Survival; Cells, Cultured; Cycloheximide; Cytoprotection; Deferoxamine; Drug Interactions; Enzyme Inhibitors; Hydrogen Peroxide; Hydroxybenzoates; Hypoxia-Inducible Factor 1; Indazoles; Mice; Oxidative Stress; Signal Transduction; Vascular Endothelial Growth Factor A | 2010 |
Hypoxia-inducible factor 1 mediates increased expression of NADPH oxidase-2 in response to intermittent hypoxia.
Topics: Animals; Carotid Body; Central Nervous System; Deferoxamine; Digoxin; Enzyme Inhibitors; Fibroblasts; Furans; Gene Expression Regulation; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NADPH Oxidase 2; NADPH Oxidases; PC12 Cells; Peripheral Nervous System; Rats; Reactive Oxygen Species; Siderophores; Sleep Apnea Syndromes | 2011 |
YC-1 sensitizes the antitumor effects of boron neutron capture therapy in hypoxic tumor cells.
Topics: Antineoplastic Agents; Boron Neutron Capture Therapy; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deferoxamine; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Large Neutral Amino Acid-Transporter 1; MCF-7 Cells; Neoplasms; Neutrons; Oxygen; Phenylalanine; Radiation-Sensitizing Agents; RNA, Small Interfering | 2020 |